ipriflavone ipriflavone ipriflavone (inn, jan; brand name yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption, maintain bone density and to prevent osteoporosis in postmenopausal women. it is not used to treat osteoporosis. it slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass. ipriflavoneclinical datatrade namesyambolapother namesfli13; 7-isopropoxyisoflavoneahfs/drugs.cominternational drug namesatc codem05bx01 (who) legal statuslegal status us: not fda approved rx-only in japan identifiers iupac name 7-isopropoxy-3-phenyl-4h-chromen-4-one cas number35212-22-7 npubchem cid3747chemspider3616 nunii80bj7wn25zkeggd01338 ychemblchembl165790 ncomptox dashboard (epa)dtxsid5040679 echa infocard100.125.854 chemical and physical dataformulac18h16o3molar mass280.323 g·mol−13d model (jsmol)interactive image smiles cc(c)oc1=cc2=c(c=c1)c(=o)c(=co2)c3=cc=cc=c3 inchi inchi=1s/c18h16o3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12h,1-2h3 nkey:sfbodokjtyaucm-uhfffaoysa-n n ny (what is this?) (verify) a clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis. a double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers. ipriflavone has been described as a phytoestrogen. however, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women. the drug prevents bone loss via mechanisms that are distinct from those of estrogens.